Ascentage Pharma GR-ADRAAPG
13F holders, Q1 2025 (March 31)6holders
$21.95avg. 13F price*
At the end of Q1 2025, 6 institutions reported holding Ascentage Pharma GR-ADR (AAPG) in their 13F filings. The largest holders were Monashee Investment Management LLC ($3.5M), Point72 (DIFC) Ltd ($558K) and XY Capital Ltd ($516K).
- Company
- Ascentage Pharma GR-ADR
- CUSIP
- 04390B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $5.2M |
| Exits | 0 | $0 |
Ownership 6 holders
| Monashee Investment Management LLC | 0.42% | New | 159,942 | $3.5M |
| Point72 (DIFC) Ltd | 0.05% | New | 25,404 | $558K |
| XY Capital Ltd | 0.34% | New | 23,505 | $516K |
| Voloridge Investment Management, LLC | 0.00% | New | 15,943 | $350K |
| Verition Fund Management LLC | 0.00% | New | 9,922 | $218K |
| UBS Group AG | 0.00% | New | 2,478 | $54K |
"% of holder's portfolio" is AAPG's weight in each manager's 13F, not the share of Ascentage Pharma GR-ADR the manager owns.